A number of studies have argued that in cancer, particularly in the context of VHL deletion, HIF-2α can act as the driver for malignant cell progression and tumor angiogenesis (Haase, 2006; Kondo et al., 2002; Smith et al., 2005). The gene discussed is EPAS1; the disease is cancer.